Recently, the application of the liposomal delivery system in the management of skin melanoma has been widely investigated. This article is a review on liposome-based therapeutic approaches against malignant melanoma.
According to this recent study, inhibition of nucleotide-binding domain, leucine-rich containing family, pyrin domain-containing-3 (NLRP3) can augment the efficacy of anti–PD-1 therapy.
This recent study pooled data from six clinical trials of anti-PD-1-based immunotherapy or BRAF/MEK targeted therapy. The aim was to show the association among pathological response, recurrence-free survival and overall survival with neoadjuvant therapy in melanoma. The study concludes that pathological response should be an early surrogate endpoint for clinical trials and a new benchmark for development and approval in melanoma.
“Over-calling” and “under-calling” of melanoma may harm individuals and healthcare systems. According to this recent study, interventions to improve histopathology agreement may reduce melanoma “over‐calling” and “under‐calling”.
Authors of this recent study investigated the function of Utrophin (UTRN), a tumor suppressor gene, in melanoma growth and the relevant molecular mechanisms. They conclude that UTRN could serve as a tumor suppressor and novel prognostic biomarker for melanoma patients.
The purpose of this recent study was to evaluate the effect of the technological evolution on sentinel lymph node biopsy in the head and neck region. It concludes that the use of advanced detection technologies led to a higher number of identified sentinel lymph nodes without increase in overall operation time, which may indicate improved surgical efficiency.
Runt-related transcription factor-3 (Runx3) is a tumor suppressor, and its contribution to melanoma progression remains unclear. According to this recent study, self-entrapping of metastatic Runx3-negative melanoma cells via adhesion and the actin cytoskeleton could be a powerful therapeutic strategy.
According to to this recent study, deep learning for dermatologist-level detection of suspicious pigmented skin lesions from wide-field images could allow for rapid and accurate assessments of pigmented lesion suspiciousness within a primary care visit. It could also enable improved patient triaging, utilization of resources, and earlier treatment of melanoma.
According to this recent study, metformin is associated with decreased risk of basal cell carcinoma (BCC)development, even at low doses. Metformin might have potential as a chemoprotective agent for patients at high risk of BCC, although this will need confirmation in future studies.
Immunotherapy in the form of checkpoint inhibitors ipilimumab, nivolumab, and pembrolizumab have been shown to improve recurrence-free survival for node-positive melanoma in the adjuvant setting and are the focus of this review.